Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

Clinical Infectious Diseases

Volumn 20, Issue 2, 1995, Pages 250-254

  Paterson, David L ^a   Georghiou, Paul R ^a   Allworth, Anthony M ^a   Kemp, Richard J ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

APHTHOUS ULCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG USE; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH;

ADULT; HIV INFECTIONS; HIV-1; HUMAN; MALE; MIDDLE AGE; RECURRENCE; RETROSPECTIVE STUDIES; STOMATITIS, APHTHOUS; THALIDOMIDE;

EID: 0028836889     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.2.250     Document Type: Article

References (38)

1. Burley DM. Dennison TC. Harrison W. Clinical experience with a new sedative drug. The Practitioner 1959; 183:57-61.
2. Mc Bride WG. Thalidomide and congenital abnormalities [letter]. Lancet 1961;2:1358.
3. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-6.
4. Vogelsang GB., Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
5. Bessis D, Guillot B, Monpoint S, Dandurand M, Guilhou JJ. Thalidomide for systemic lupus erythematosus [letter]. Lancet 1992; 339:549-50.
6. Rustin MHA, Gilkes JJH, Robinson TWE. Pyoderma gangrenosum associated with Behcet’s disease: treatment with thalidomide. J Am Acad Dermatol 1990;23:941-4.
7. Tamura F, Vogelsang GB, Reitz BA, Baumgartner WA, Herskowitz A. Combination thalidomide and cyclosporine for cardiac allograft rejection: comparison with combination methylprednisolone and cyclosporine. Transplantation 1990;49:20-5.
8. Georghiou PR, Kemp RJ. HIV-associated oesophageal ulcers treated with thalidomide [letter]. Med J Aust 1990; 152:382-3.
9. Georghiou PR, Allworth AM. Thalidomide in painful AIDS-associated proctitis [letter], J Infect Dis 1992; 166:939-40.
10. Harindra V, Roy RB. Papulo-pruritic eruption and giant ulceration of the mouth: a difficult clinical feature to treat in the patient infected with human immunodeficiency virus [letter]. Arch Intern Med 1992; 152:1924.
11. Youle M, Clarbour J, Farthing C, etal. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989:298:432.
12. Connolly GM, Hawkins D, Harcourt-Webster JN. Parsons PA, Husain OAN, Gazzard BG. Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut 1989;30:1033-9.
13. Gorin I, Vilette B, Gehanno P, Escande JP. Thalidomide in hyperalgic pharyngeal ulceration of AIDS [letter]. Lancet 1990; 335:1343.
14. Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide. J Am Acad Dermatol 1990;23:523-5.
15. Williams I, Weller IVD, Malin A, Anderson J, Waters MFR. Thalidomide hypersensitivity in AIDS [letter]. Lancet 1991;337:436-7.
16. Nicolau DP, West TE. Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. Drug Intelligence and Clinical Pharmacy 1990;24:1054-6.
17. Ryan J, Colman J. Pedersen J, Benson E. Thalidomide to treat esophageal ulcer in AIDS [letter], N Engl J Med 1992;327:208-9.
18. Bouza E, Munoz P, Diaz MD, Vicente T. Thalidomide in patients with acquired immunodeficiency syndrome [letter]. Arch Intern Med 1992;152:1089-90.
19. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36(suppl 1S): 1S-15S.
20. Phelan JA, Saltzman BR, Friedland GH. Klein RS. Oral findings in patients with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol 1987;64:50-6.
21. Law CLH, Qassim M, Cunningham AL, Mulhall B, Grierson JM. Nonspecific proctitis: association with human immunodeficiency virus infection in homosexual men. J Infect Dis 1992; 165:150-4.
22. Rabeneck L, Popovic M, Gartner S, et al. Acute HIV infection presenting with painful swallowing and esophageal ulcers. JAMA 1990;263:2318-22.
23. Rabeneck L, Boyko WJ, McLean DM, McLeod WA, Wong KK. Unusual esophageal ulcers containing enveloped viruslike particles in homosexual men. Gastroenterology 1986;90:1882-9.
24. Youle M, Hawkins D, Gazzard B. Thalidomide in hyperalgic pharyngeal ulceration of AIDS [letter]. Lancet 1990; 335:1591.
25. Sokol-Anderson ML, Prelutsky DJ, Westblom TU. Giant esophageal aphthous ulcers in AIDS patients: treatment with low-dose corticosteroids [letter], AIDS 1991;5:1537-8.
26. Mac Phail LA, Greenspan D, Feigal DW, Lennette ET, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection: description of ulcer types and analysis of T-lymphocyte subsets. Oral Surg Oral Med Oral Pathol 1991;71:678-83.
27. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis [letter]. Arch Dermatol 1979; 115:636-7.
28. Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PDL, Smith NJ. Thalidomide in severe orogenital ulceration. Lancet 1984; 2:1424-6.
29. Waters MFR. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971; 42:26-42.
30. Fullerton PM, O’Sullivan DJ. Thalidomide neuropathy: a clinical, elec- trophysiological, and histological follow-up study. J Neurol Neuro- surg Psych 1968;31:543-51.
31. Crawford CL. Thalidomide neuropathy [letter], N Engl J Med 1992; 327:735.
32. Fuller GN, Jacobs JM, Guiloff RJ. Thalidomide, peripheral neuropathy and AIDS. Int J STD AIDS 1991;2:369-70.
33. Giinzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Safety 1992; 7:116-34.
34. Giinzler V. Thalidomide—a therapy for the immunological consequences of HI V infection? Med Hypotheses 1989; 30:105-9.
35. Vicente T, Ortega A, Munoz P, Diaz MD, Bouza E. In vitro activity of thalidomide against Mrcobaclerium avium complex [letter]. Arch Intern Med 1993:153:534.
36. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
37. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
38. Hawkins DF. Thalidomide for systemic lupus erythematosus [letter]. Lancet 1992; 339:1057.